Intersect Capital’s Filana Therapeutics FLNA Stock Holding History

Intersect Capital’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-4,200	Closed	-$359K	–	414
2021 Q2	$359K	Buy	+4,200	New	+$225K	0.06%	230

Other funds holding FLNA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Intersect Capital's FLNA Position: Q3 2021 in Review

Intersect Capital sold out of Filana Therapeutics (FLNA) in Q3 2021, closing a stake of 2,252 shares — an estimated $192K sold.

Intersect Capital first reported a position in FLNA in Q3 2020 and held it in 3 quarters. The position peaked at $230K in Q3 2020. 180 funds tracked by Wall St. Rank hold FLNA as of Q3 2021.

Intersect Capital reported no remaining Filana Therapeutics position as of Q3 2021 after selling out during the quarter.
Intersect Capital sold 2,252 Filana Therapeutics shares in Q3 2021, an estimated $192K.
Intersect Capital first reported a position in Filana Therapeutics in Q3 2020 and held it in 3 quarters.
Intersect Capital's Filana Therapeutics position peaked at $230K in Q3 2020.
180 funds tracked by Wall St. Rank held Filana Therapeutics as of Q3 2021.

Based on Intersect Capital's 13F filing for Q3 2021, filed 15 Oct 2021.